Core Insights - TSMC is shifting its focus towards advanced processes and will gradually outsource some 40-90nm orders to its subsidiary, World Advanced [1][3] - TSMC has announced the suspension of its 6-inch wafer fab in Hsinchu and plans to exit the GaN foundry business within two years, reallocating resources to higher-margin businesses [1][4] Industry Performance - The chemical sector performed well this week, with the Shenwan Chemical Index rising by 3.54%, outperforming the CSI 300 Index by 0.82% [2] - Short-term macro policies are relatively stable, with a focus on three key tracks: growth in terminal industries like robotics and AI, low-valuation cyclical sectors, and actual changes in industry fundamentals such as the lithium battery supply chain [2] Major Events - TSMC's exit from mature processes marks a significant strategic shift, focusing on higher-margin business areas [3][4] - The Dutch government anticipates that Ansem China will soon resume chip supplies, with constructive talks with China [4] - The U.S. government is evaluating military options against Venezuela, including seizing oil fields, leading to a slight increase in WTI crude oil prices [4]

Core Insights - The pharmaceutical industry is complex, with cyclical fluctuations in raw materials, high-tech characteristics of innovative drugs, and the consumer nature of medical services intertwining, making market predictions and investment management challenging [1] - Jiang Qi, a fund manager at Dongfanghong Asset Management, has developed a precise investment strategy in the pharmaceutical sector through years of industry experience [1] Group 1: Investment Strategy - The core of pharmaceutical investment lies in understanding cyclical fluctuations and long-term trends, which is essential for constructing resilient investment portfolios [2] - Jiang Qi's investment logic emphasizes a "top-down approach to selecting sectors and a bottom-up approach to selecting companies," with policy direction and growth potential as key indicators of sector value [2] - Historical trends show clear sector rotations, with innovative drugs and consumer upgrades becoming the main focus post-2019, and traditional Chinese medicine gaining traction due to policy support from 2022 to 2023 [2] Group 2: Long-term Outlook - Long-term returns in the pharmaceutical industry stem from technological growth, with companies that continuously break through technical barriers and create clinical value being the most resilient [3] - A diversified portfolio is necessary to navigate market volatility, balancing growth stocks' explosive potential with the defensive strength of undervalued assets [3] Group 3: Innovation Focus - The key variable for investment success in the current phase is innovative drugs, which have transitioned from quantitative accumulation to qualitative breakthroughs since 2015 [4] - Investment in innovative drugs should move beyond traditional valuation frameworks, focusing on global competitiveness, clinical value, and commercialization potential [4] - Recent strategic collaborations between Chinese innovative drug companies and multinational pharmaceutical firms highlight the increasing credibility of Chinese clinical data and global competitiveness [4] Group 4: Future Projections - By the second half of 2025, the direction of the innovative drug industry is expected to become clearer, supported by technological advancements and improved clinical resources [5] - The upcoming reforms in commercial health insurance are anticipated to significantly impact the industry, similar to the 2015 clinical trial data verification initiative [5] - The period from 2025 to 2029 is projected to be the first phase of harvest for the innovative drug sector, following a decade of investment from 2015 to 2024 [5] Group 5: Value Preservation - The ultimate goal of investment is to focus on long-term value rather than short-term gains, especially in the face of high uncertainty in the pharmaceutical industry [6] - Risk control is crucial, with a focus on left-side positioning and in-depth research to uncover opportunities during industry downturns [7] - The long-term value anchor remains the clinical value and growth potential created by companies, addressing unmet health needs through innovation and service upgrades [7]